Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model

Jason V. Brooks, Ian M. Orme
Jason V. Brooks
Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian M. Orme
Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.42.11.3047
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Once-weekly therapy with combinations of isoniazid plus a rifamycin was tested in the mouse low-dose aerosol infection model against two strains of Mycobacterium tuberculosis. Combinations of isoniazid and rifalizil and isoniazid and rifapentine were both highly effective. These animal model data thus support the evaluation of these regimens under clinical conditions.

The therapy of disease caused byMycobacterium tuberculosis is now further complicated by the emergence of increasing drug resistance. One of the factors contributing to this specific problem, and indeed to the therapy of tuberculosis as a whole, is patient compliance (1). To address this issue, the World Health Organization has instigated a program of directly observed therapy (2, 3, 5, 6, 14, 20).

Among approaches to encourage patient compliance are shortening the therapy period (some regimens in the past have required a year or more of daily treatment) and lengthening the period between doses, e.g., instituting once-weekly therapy. This latter approach is particularly attractive in areas of the world, such as Africa, in which patients may be widely dispersed in rural areas away from the nearest clinic (8, 10, 17, 24, 25).

In this study, we used the mouse aerosol infection model (18) to evaluate the combination of isoniazid and the newly available rifamycins (4, 7, 9, 11-13, 15, 16, 19, 21, 22) given once weekly. Combinations of isoniazid with rifapentine (RPT) or rifalizil (RLZ) were the most effective in this model. These data suggest that such regimens are indeed worthy of evaluation in clinical trials.

Female specific-pathogen-free C57BL/6 mice (Jackson Laboratories, Bar Harbor, Maine) were aerogenically infected with M. tuberculosis Erdman (TMC107) or the highly virulent (drug-sensitive) strain CSU93 (23) with a Middlebrook aerosol generation device (Glas-Col Inc., Terre Haute, Ind.). Mice were exposed to a standardized inoculum that reproducibly deposits 50 to 100 bacilli into the lung tissues. The course of the infection was then monitored against time by plating serial dilutions of individual whole-organ homogenates on nutrient 7H11 agar and counting bacterial colony formation 14 to 21 days later after incubation at 37°C in humidified air. RLZ, previously designated KRM-1648, was provided by PathoGenesis Corp., Seattle, Wash.; rifampin (RIF) was purchased from Sigma Chemical Co., St. Louis, Mo. RPT was provided by Hoechst Marion Roussel, Inc., Cincinnati, Ohio; rifabutin (RBT) was provided by Pharmacia Upjohn, Columbus, Ohio. The MICs (of RIF, 0.125 μg; of RPT, 0.03 μg; of RBT, 0.03 μg; and of RLZ, 0.008 μg), determined by plating inocula onto agar containing dilutions of drug, for the two strains were similar. For use in vivo, each drug was initially dissolved in a small volume of ethanol and then further dissolved in 0.05% methylcellulose and 0.04% Tween 80 in distilled water prior to oral gavage. Therapy, started at week 3, was given once weekly for 5 weeks. All drugs were given at a dose of 25 mg/kg of body weight/day.

The results of the study are shown in Fig.1. One week after the 5-week therapy period was discontinued, mice given the isoniazid-RLZ or isoniazid-RPT combination showed clearance in the lungs of the CSU93 strain and only a few detectable Erdman bacilli. Animals treated with isoniazid and RIF or isoniazid and RBT also showed clearance, but to a much lesser degree. A similar pattern of clearance was seen in the spleen. Bacteria in mice disseminate to this organ and can usually be detected a few weeks into infection. Bacteria were detectable in all mice at day 35 (2 weeks into therapy), but these were then cleared in a pattern similar to that seen in the lungs, again with isoniazid-RLZ and isoniazid-RPT being the most-effective drugs. These animal model data therefore support the evaluation of these regimens as intermittent therapy in clinical trials.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Growth of M. tuberculosis CSU93 and Erdman following aerosol exposure of C57BL/6 mice and the effects of therapy (given from days 21 to 56). INH, isoniazid. All drugs were given at a dose of 25 mg/kg/day. Data are expressed as mean values ( n = 4; standard errors of the mean, omitted for clarity, did not exceed 0.45).

ACKNOWLEDGMENTS

This work was supported by NIH programs AI-45239 and AI-45244.

We thank Rick O’Brien for suggesting this study.

FOOTNOTES

    • Received 21 April 1998.
    • Returned for modification 22 July 1998.
    • Accepted 18 August 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Buchanan R. J.
    Compliance with tuberculosis drug regimens: incentives and enablers offered by public health departments. Am. J. Public Health 87 1997 2014 2017
    OpenUrlPubMedWeb of Science
  2. 2.↵
    1. Burman W. J.,
    2. Dalton C. B.,
    3. Cohn D. L.,
    4. Butler J. R.,
    5. Reves R. R.
    A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 112 1997 63 70
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Caminero J. A.,
    2. Pavon J. M.,
    3. Rodriguez de Castro F.,
    4. Diaz F.,
    5. Julia G.,
    6. Cayla J. A.,
    7. Cabrera P.
    Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax 51 1996 1130 1133
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Chapuis L.,
    2. Ji B.,
    3. Truffot-Pernot C.,
    4. O’Brien R. J.,
    5. Raviglione M. C.,
    6. Grosset J. H.
    Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am. J. Respir. Crit. Care Med. 150 1994 1355 1362
    OpenUrlPubMedWeb of Science
  5. 5.↵
    1. Chaulk C. P.,
    2. Moore-Rice K.,
    3. Rizzo R.,
    4. Chaisson R. E.
    Eleven years of community-based directly observed therapy for tuberculosis. JAMA 274 1995 945 951
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Cohn D. L.,
    2. Catlin B. J.,
    3. Peterson K. L.,
    4. Judson F. N.,
    5. Sbarbaro J. A.
    A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann. Intern. Med. 11 2 1990 407 415
    OpenUrl
  7. 7.↵
    1. Dhillon J.,
    2. Mitchison D. A.
    Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am. Rev. Respir. Dis. 145 1992 212 214
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Dick J.,
    2. Clarke M.,
    3. Tibbs J.,
    4. Schoeman H.
    Combating tuberculosis—lessons learnt from a rural community project in the Klein Drakenstein area of the Western Cape. S. Afr. Med. J. 87 1997 1042 1047
    OpenUrlPubMedWeb of Science
  9. 9.↵
    1. Dickinson J. M.,
    2. Mitchison D. A.
    In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle 68 1987 183 193
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Ellis J. H.,
    2. Beyers N.,
    3. Bester D.,
    4. Gie R. P.,
    5. Donald P. R.
    Sociological and anthropological factors related to the community management of tuberculosis in the Western Cape communities of Ravensmead and Uitsig. S. Afr. Med. J. 87 1997 1047 1051
    OpenUrlPubMed
  11. 11.↵
    1. Gonzalez-Montaner L. J.,
    2. Natal S.,
    3. Yongchaiyud P.,
    4. Olliaro P.
    Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis. 75 1994 341 347
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Heifets L. B.,
    2. Lindholm-Levy P.,
    3. Flory M. A.
    Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141 1990 626 630
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Hirata T.,
    2. Saito H.,
    3. Tomioka H.,
    4. Sato K.,
    5. Jidoi J.,
    6. Hosoe K.,
    7. Hidaka T.
    In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39 1995 2295 2303
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Iseman M. D.
    Directly-observed therapy, patient education and combined drug formulations: complementary, not alternative, strategies in tuberculosis control. Tubercle Lung Dis. 77 1996 101
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Jabes D.,
    2. Della Bruna C.,
    3. Rossi R.,
    4. Olliaro P.
    Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. Antimicrob. Agents Chemother. 38 1994 2346 2350
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Ji B.,
    2. Truffot-Pernot C.,
    3. Lacroix C.,
    4. Raviglione M. C.,
    5. O’Brien R. J.,
    6. Olliaro P.,
    7. Roscigno G.,
    8. Grosset J.
    Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148 1993 1541 1546
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Johansson E.,
    2. Diwan V. K.,
    3. Huong N. D.,
    4. Ahlberg B. M.
    Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam. Tubercle Lung Dis. 77 1996 178 183
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Kelly B. P.,
    2. Furney S. K.,
    3. Jessen M. T.,
    4. Orme I. M.
    Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40 1996 2809 2812
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Klemens S. P.,
    2. Grossi M. A.,
    3. Cynamon M. H.
    Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38 1994 2245 2248
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Nowak R.
    WHO calls for action against TB. Science 267 1995 1763
    OpenUrlFREE Full Text
  21. 21.↵
    1. Orme I. M.
    Antimycobacterial activity in vivo of LM427 (rifabutin). Am. Rev. Respir. Dis. 138 1988 1254 1257
    OpenUrlPubMed
  22. 22.↵
    1. Pretet S.,
    2. Lebeaut A.,
    3. Parrot R.,
    4. Truffot C.,
    5. Grosset J.,
    6. Dinh-Xuan A. T.
    Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Eur. Respir. J. 5 1992 680 684
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Valway S. E.,
    2. Sanchez M. P. C.,
    3. Shinnick T. F.,
    4. Orme I. M.,
    5. Agerton T.,
    6. Hoy D.,
    7. Jones J. S.,
    8. Westmoreland H.,
    9. Onorato I. M.
    An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338 1998 633 639
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Wilkinson D.,
    2. Anderson E.,
    3. Davies G. R.,
    4. Sturm A. W.,
    5. McAdam K. P.
    Efficacy of twice weekly treatment for tuberculosis given under direct observation in Africa. Trans. R. Soc. Trop. Med. Hyg. 91 1997 87 89
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Wilkinson D.,
    2. Davies G. R.,
    3. Connolly C.
    Directly observed therapy for tuberculosis in rural South Africa, 1991 through 1994. Am. J. Public Health 86 1996 1094 1097
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model
Jason V. Brooks, Ian M. Orme
Antimicrobial Agents and Chemotherapy Nov 1998, 42 (11) 3047-3048; DOI: 10.1128/AAC.42.11.3047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of Once-Weekly Therapy for Tuberculosis Using Isoniazid plus Rifamycins in the Mouse Aerosol Infection Model
Jason V. Brooks, Ian M. Orme
Antimicrobial Agents and Chemotherapy Nov 1998, 42 (11) 3047-3048; DOI: 10.1128/AAC.42.11.3047
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antitubercular agents
isoniazid
rifamycins
tuberculosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596